Status:
COMPLETED
Tandem Control-IQ Evaluation Regarding Glucose Metrics, Sleep, and Health Economics
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
2-19 years
Brief Summary
To evaluate Tandem Control-IQ compared with rtCGM and insulin pen respectively rtCGM and insulin pump treatment in children and adolescents regarding glucose control, sleep and health economics for 18...
Detailed Description
In this obesrvational study, the investigators assessed glycemic outcomes, sleep and health economics associated with AID treatment (Tandem Control-IQ) compared with multiple daily insulin injections ...
Eligibility Criteria
Inclusion
- Age between 2-19 years at the start
- Diagnosed with Type 1 diabetes
- Min duration three months
- Willingness to participate in the study
Exclusion
- Pregnancy
- Unwillingness to share and upload CGM data
- Reluctance to come to visit and to follow protocol
- History of allergic reaction to Dexcom CGM materials or adhesives in contact with the skin.
- Abnormal skin at the anticipated glucose sensor attachment sites(excessive hair, burn, inflammation, infection, rash, and/or tattoo)
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT05969106
Start Date
January 1 2020
End Date
December 30 2022
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The hospital of Halland Kungsbacka
Kungsbacka, Region of Halland, Sweden, 43480